Atenolol, 50 mg, b.i.d., and propranolol, 80 mg b.i.d.,. were given to 28 patients with a presumed diagnosis of migraine, in a placebo-controlled double-blind cross-over study, where each period lasted 6 weeks. In the total material, atenolol was significantly better than placebo in reducing attacks, whereas propranolol showed no definite such effect. In seven patients the number of headache days was remarkably high (average: 22 headache days in 42 days), which may indicate that they have been inappropriately included in the material or have recorded interparoxysmal headache in addition to attacks. If these patients are excluded, the attack-reducing effect of propranolol and tenormin is significant and of equal magnitude.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes of Discharged Patients With High Blood Pressure in the Emergency Department.
Cureus
December 2024
Emergency Medicine, King Abdulaziz University Hospital, Jeddah, SAU.
Background: Elevated blood pressure (BP) prompts immediate emergency department (ED) visits instead of outpatient care, thus constituting a high-weight concern for the ED. This study investigated the short- and long-term outcomes of high BP patients in the ED.
Methods: A retrospective cohort study was conducted at King Abdulaziz University Hospital (KAUH), reviewing ED visits from January to December 2022.
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis.
Expert Rev Neurother
January 2025
Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Introduction: When a first anti-CGRP monoclonal antibody (anti-CGRP mAb) fails, switching to a different anti-CGRP mAb is an option often considered, despite this approach is not yet systemically studied.
Methods: We present the findings of a systematic review conducted according to the PRISMA recommendations on published studies - of any design - investigating the clinical outcomes after switching for any reason to different anti-CGRP mAbs.
Results: The literature search retrieved 76 records, while 19 papers were eventually reviewed.
Concurrent transmission of Zika virus during the 2023 dengue outbreak in Dhaka, Bangladesh.
PLoS Negl Trop Dis
January 2025
Infectious Diseases Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Background: During the 2023-dengue outbreak in Bangladesh, a diagnostic evaluation study was conducted to investigate concurrent Zika virus (ZIKV) and dengue virus (DENV) transmission in Dhaka in 2023.
Aims: The study explored to simultaneously detect the presence of ZIKV, DENV, and/or CHIKV while considering relevant clinical and epidemiological risk factors, using a real-time multiplex RT-PCR system. Following this, it was planned to sequence the selected samples to identify genetic variations of the ZIKV infections within the population.
Multidimensional Classification and Prediction of Outcome Following Traumatic Brain Injury.
J Head Trauma Rehabil
January 2025
Author Affiliations: Monash-Epworth Rehabilitation Research Centre, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia (Prof Ponsford and Drs Spitz, Pyman, Carrier, Hicks, and Nguyen); Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia (Dr Spitz); TIRR Memorial Hermann Research Center Houston, Texas (Drs Sander and Sherer); and H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine & Harris Health System, Houston, Texas (Drs Sander and Sherer).
Objectives: This study aimed to identify outcome clusters among individuals with traumatic brain injury (TBI), 6 months to 10 years post-injury, in an Australian rehabilitation sample, and determine whether scores on 12 dimensions, combined with demographic and injury severity variables, could predict outcome cluster membership 1 to 3 years post-injury.
Setting: Rehabilitation hospital.
Participants: A total of 467 individuals with TBI, aged 17 to 87 (M = 44.
Peripartum Cardiomyopathy and Takotsubo Cardiomyopathy: Rare Contributors to Cardiac Causes of Maternal Mortality.
Cureus
December 2024
Neurology, Mercy Hospital Springfield, Springfield, USA.
Peripartum cardiomyopathy (PPCM) and takotsubo cardiomyopathy (TCM) are cardiac conditions that can occur in the peripartum period. They have distinct characteristics and incidence rates; although rare, both contribute to the second leading cause of all-cause maternal mortality in the state of Missouri. PPCM can lead to heart failure, and TCM can cause acute arrhythmias leading to sudden cardiac death in otherwise healthy individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!